Our Science
Restoring synaptic function to reverse cognitive decline.
Synaptic Repair Approach
EngramBio is built on the evidence that synapse dysfunction is an early and reversible driver of cognitive decline in Alzheimer's disease and related dementias. Currently, there are no approved therapeutics that directly repair synapses. Rather than targeting aggregated proteins associated with disease, our approach focuses on restoring synaptic function and increasing brain resilience to neurodegeneration.
KIBRA-Derived Therapeutics
EngramBio's lead program is based on KIBRA, a synaptic protein essential for learning and memory. Our KIBRA-derived peptide has been shown to repair synaptic plasticity, reverse synapse loss, and reverse memory deficits in disease-relevant models. We evaluate therapeutic efficacy using human iPSC-derived neurons, electrophysiology, and behavioral studies in mouse models.
Advancing Synapse Repair
By integrating rigorous mechanistic biology with AI-guided drug optimization and clinically relevant biomarkers that reflect synapse health and function, EngramBio is advancing a new class of synapse repair therapeutics. These treatments will be designed to preserve memory and improve outcomes for patients experiencing memory loss.
